Kronos Bio is advancing three investigational compounds in clinical trials for patients with cancer. The company’s lead compound, the SYK inhibitor entospletinib, is being evaluated in the registrational Phase 3 AGILITY trial for newly diagnosed NPM1-mutated acute myeloid leukemia (AML). The company is also developing the CDK9 inhibitor, KB-0742, and lanraplenib, a next-generation SYK inhibitor. Kronos Bio’s scientific focus is the dysregulated transcription that is the hallmark of cancer.